Medicus Pharma Business Update Call Highlights 80% ORR in Phase 2 SkinJect Study and AI-Enabled Drug Development

on

Medicus Pharma hosted a business update conference call on March 26, 2026, at 11:
30 a.m. ET to highlight an 80% Overall Response Rate (ORR) in the Phase 2 SKNJCT-003 SkinJect study for basal cell carcinoma.14

Topline results from SKNJCT-003 showed 73% clinical clearance and 40% histological complete response in the 200µg cohort at Day 57, with full Clinical Study Report expected in Q2 2026.35

The company plans an End-of-Phase 2 meeting with the FDA in H1 2026 for SkinJect.32

Medicus is pursuing an AI-driven clinical analytics platform via a letter of intent with Reliant AI to enhance site selection and patient enrollment.3

Additional progress includes FDA clearance for Phase 2b trials of Teverelix in prostate cancer and acute urinary retention relapse.35

The update accompanies full-year 2025 financial results reported via Form 10-K on March 25, 2026.156

Sources:

1. https://firstwordpharma.com/story/7147710

2. https://medicuspharma.com/investor-relations/press-releases/

3. https://www.marketscreener.com/news/razorpitch-medicus-pharma-mdcx-a-small-cap-biotech-making-moves-in-2026-ce7e51dadb81f22c

4. https://www.marketbeat.com/earnings/reports/2026-3-25-medicus-pharma-ltd-stock/

5. https://www.stocktitan.net/sec-filings/MDCX/424b3-medicus-pharma-ltd-prospectus-filed-pursuant-to-rule-424-b-3-1f2a2444ff2d.html

6. https://medicuspharma.com/investor-relations/sec-filings/